Cargando…

European expert network on rare communicable diseases and other rare diseases linked to mobility and globalisation focused on health care provision (EURaDMoG): a feasibility study

INTRODUCTION: In the current mobility and globalization context, there is a growing need to identify potential changes on the pattern of diseases in the European Union (EU)/European Economic Area (EEA) and provide accurate diagnosis and treatment for the population. The pattern of rare communicable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Requena-Méndez, Ana, Bisoffi, Zeno, Vives-Corrons, Joan-Lluis, Gascon, Joaquim, Plasència, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Position Statement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563907/ https://www.ncbi.nlm.nih.gov/pubmed/33066818 http://dx.doi.org/10.1186/s13023-020-01534-1

Ejemplares similares

Epidemiology of rare diseases in Brazil: protocol of the Brazilian Rare Diseases Network (RARAS-BRDN)
por: Félix, Têmis Maria, et al.
Publicado: (2022)

Compounded medication for patients with rare diseases
por: Dooms, Marc, et al.
Publicado: (2018)

Rare diseases in Tanzania: a National Call for Action to address policy and urgent needs of individuals with rare diseases
por: Kaywanga, Frida, et al.
Publicado: (2022)

From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research
por: Kaufmann, Petra, et al.
Publicado: (2018)

eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)
por: Paglialonga, Alessia, et al.
Publicado: (2021)

Rare disease education in Europe and beyond: time to act
por: Tumiene, Birute, et al.
Publicado: (2022)

Pharmacists are initiators in palliative care for patients with rare diseases
por: Dooms, M.
Publicado: (2023)

Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER
por: Bernts, Lucas H. P., et al.
Publicado: (2019)

European Reference networks for rare diseases: what is the conceptual framework?
por: Héon-Klin, Véronique
Publicado: (2017)

A patient advocating for transparent science in rare disease research
por: Yang, Richard Rui
Publicado: (2023)

Increasing African genomic data generation and sharing to resolve rare and undiagnosed diseases in Africa: a call-to-action by the H3Africa rare diseases working group
por: Lumaka, Aimé, et al.
Publicado: (2022)

Pharmaceutical pricing, cost containment and new treatments for rare diseases in children
por: Stella, Peter, et al.
Publicado: (2014)

Rare diseases in Chile: challenges and recommendations in universal health coverage context
por: Encina, Gonzalo, et al.
Publicado: (2019)

Data silos are undermining drug development and failing rare disease patients
por: Denton, Nathan, et al.
Publicado: (2021)

Clinical management guidelines for Friedreich ataxia: best practice in rare diseases
por: Corben, Louise A., et al.
Publicado: (2022)

The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks
por: Evangelista, Teresinha, et al.
Publicado: (2016)

Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases
por: Douglas, Conor M. W., et al.
Publicado: (2022)

Sharing is caring: a call for a new era of rare disease research and development
por: Denton, Nathan, et al.
Publicado: (2022)

Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
por: Mulberg, Andrew E., et al.
Publicado: (2019)

TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases
por: Annemans, Lieven, et al.
Publicado: (2020)

The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement
por: Black, Graeme C., et al.
Publicado: (2021)

A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs
por: Cui, Yazhou, et al.
Publicado: (2015)

European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
por: Shovlin, Claire L., et al.
Publicado: (2018)

RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework
por: Bellgard, Matthew I., et al.
Publicado: (2019)

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
por: Annemans, Lieven, et al.
Publicado: (2017)

Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic
por: Brizola, E., et al.
Publicado: (2020)

Integrating rare disease management in public health programs in India: exploring the potential of National Health Mission
por: Choudhury, Mohua Chakraborty, et al.
Publicado: (2022)

Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium
por: Rudebeck, Mattias, et al.
Publicado: (2021)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients
por: Zanello, Galliano, et al.
Publicado: (2022)

Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force
por: Nabbout, Rima, et al.
Publicado: (2023)

Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures
por: Morel, Thomas, et al.
Publicado: (2017)

European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants
por: van de Laar, Ingrid M. B. H., et al.
Publicado: (2019)

Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease
por: Spineli, Loukia M., et al.
Publicado: (2017)

European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT)
por: Eker, Omer F., et al.
Publicado: (2020)

Expansion of India’s national child healthcare programme, Rashtriya Bal Swasthya Karyakram (RBSK), for rare disease management : a health policy perspective
por: Chaube, Pragya, et al.
Publicado: (2023)

The German National Action League for people with rare diseases: translating the three tiers center system into active co-operation, a one center experience
por: Plöckinger, U., et al.
Publicado: (2019)

The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force
por: Southall, Noel T, et al.
Publicado: (2019)

Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives?
por: Di Rocco, Maja, et al.
Publicado: (2020)

French recommendations for the management of Behçet’s disease
por: Kone-Paut, Isabelle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dhf6ar378prrsie9o84r1bo8l3